Teshima Takahiro
Laboratory of Veterinary Internal Medicine, School of Veterinary Medicine, Faculty of Veterinary Science, Japan; Research Center for Animal Life Science, Nippon Veterinary and Life Science University, Musashino, Tokyo 180-8602, Japan.
Vet J. 2024 Apr;304:106090. doi: 10.1016/j.tvjl.2024.106090. Epub 2024 Feb 28.
Inflammatory bowel disease (IBD) is a major subtype of chronic enteropathies in dogs and cats. Conventional drugs such as immunomodulatory medicines as glucocorticoids and/or other anti-inflammatory are mainly applied for treatment. However, these drugs are not always effective to maintain remission from IBD and are limited by unacceptable side effects. Hence, more effective and safe therapeutic options need to be developed. Mesenchymal stem cells (MSCs) are multipotent stem cells with a self-renewal capacity, and have immunomodulatory, anti-inflammatory, anti-fibrotic, and tissue repair properties. Therefore, the application of MSCs as an alternative therapy for IBD has great potential in veterinary medicine. The efficacy of adipose tissue-derived MSC (ADSC) therapy for IBD in dogs and cats has been reported, including numerous studies in animal models. However, treatment outcomes in clinical trials of human IBD patients have not been consistent with preclinical studies. MSC-based therapy for various diseases has received widespread attention, but various problems in such therapy remain, among which no consensus has been reached on the preparation and treatment procedures for MSCs, and cellular heterogeneity of MSCs may be an issue. This review describes the current status of ADSC therapy for canine and feline IBD and summarizes the cellular heterogeneity of canine ADSCs, to highlight the necessity for further reduction or elimination of MSCs heterogeneity and standardization of MSC-based therapies.
炎症性肠病（IBD）是犬猫慢性肠病的主要亚型。传统药物如免疫调节药物如糖皮质激素和/或其他抗炎药物主要用于治疗。然而，这些药物并不总是能有效维持IBD的缓解，且受到不可接受的副作用的限制。因此，需要开发更有效和安全的治疗选择。间充质干细胞（MSCs）是具有自我更新能力的多能干细胞，具有免疫调节、抗炎、抗纤维化和组织修复特性。因此，将MSCs作为IBD的替代疗法在兽医学中具有巨大潜力。脂肪组织来源的间充质干细胞（ADSCs）治疗犬猫IBD的疗效已有报道，包括在动物模型中的大量研究。然而，人类IBD患者临床试验的治疗结果与临床前研究并不一致。基于MSCs的各种疾病治疗已受到广泛关注，但这种治疗中仍存在各种问题，其中关于MSCs的制备和治疗程序尚未达成共识，MSCs的细胞异质性可能是一个问题。本综述描述了ADSCs治疗犬猫IBD的现状，并总结了犬ADSCs的细胞异质性，以强调进一步减少或消除MSCs异质性以及基于MSCs的治疗标准化的必要性。
